Effects and Safety of a Novel Oral Potassium-Lowering Drug-Sodium Zirconium Cyclosilicate for the Treatment of Hyperkalemia: a Systematic Review and Meta-Analysis
ConclusionsSZC effectively decreased the sK+ level in patients with hyperkalemia within 48 h and had benefits in the long-term control of serum potassium in patients who continued to receive SZC with a favorable safety profile from available data.
Source: Cardiovascular Drugs and Therapy - Category: Cardiology Source Type: research
More News: Cardiology | Cardiovascular | Chronic Kidney Disease | Databases & Libraries | Diabetes | Endocrinology | Heart | Potassium | Sodium | Statistics | Study | Urology & Nephrology